Orca Bio announced that the @fda.gov has accepted for Priority Review the Biologics License Application for Orca-T, an allogeneic T-cell immunotherapy to treat #HematologicCancers, including #ALL, #MDS, and #AML.
Learn more: https://bit.ly/3IN9jmx
#RareDisease #PriorityReview #OrcaT #Oncology